Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
25 févr. 2021 16h01 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended...
NapaJen Pharma Reports Positive Results from Phase 1 Clinical Trial of Novel RNA Interference (RNAi) Therapeutic
08 oct. 2020 07h35 HE
|
NapaJen
NJA-730 is an Anti-CD-40 Oligonucleotide Combined with Beta-Glucan Delivery Vehicle with Potential to Treat Acute Graft-versus-Host Disease (aGvHD) Treatment Shown to be Safe and Well-Tolerated...
MicroCures Advances Burn Wound Healing Program Under Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR)
28 janv. 2020 08h05 HE
|
MicroCures, Inc.
$1 Million in Funding from the USAISR Supporting Collaborative Research Project Pilot Animal Study Successfully Completed; Larger Preclinical Study Underway NEW YORK, Jan. 28, 2020 (GLOBE...
MicroCures Announces Issuance of New Patent Covering First-of-its-Kind Cell Movement Decelerator Technology with Potential Applications in Oncology and Fibrosis
14 janv. 2020 08h05 HE
|
MicroCures, Inc.
New Japanese Patent Further Strengthens Intellectual Property Portfolio Covering Company’s Novel Platform for Precisely Controlling Core Cell Migration Mechanisms Decelerator Technology Serves as...
MicroCures Awarded $1.5M SBIR Grant To Support Development of Novel Therapeutic Platform for Accelerated Tissue Repair
07 janv. 2020 08h05 HE
|
MicroCures, Inc.
NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- MicroCures, a biopharmaceutical company developing novel therapeutics that harness the body’s innate regenerative mechanisms to accelerate tissue repair,...
NapaJen Pharma Announces First Patient Dosed in Phase 1 First-in-Human Clinical Trial of Novel RNA Interference (RNAi) Therapeutic
15 nov. 2018 07h35 HE
|
NapaJen
NJA-730 is an Anti-CD-40 Small Interfering RNA (siRNA) Combined with Beta-Glucan Delivery Vehicle with Potential to Treat Acute Graft-versus-Host Disease Program Leverages NapaJen’s Immune...
Aphios Granted United States Patent for Improved Delivery of Targeted siRNA Using Nanotechnology
05 juin 2018 08h00 HE
|
Aphios
WOBURN, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Aphios Corporation today announced that it has been granted United States Patent No. 9,981,238 entitled “Apparatus and Methods for Making Nanosomes...
MDRNA, Inc. Appoints James M. Karis to Its Board of Directors
11 août 2009 09h15 HE
|
MDRNA, Inc.
BOTHELL, WA--(Marketwire - August 11, 2009) - MDRNA, Inc. (NASDAQ: MRNA) announced today that
James M. Karis has been appointed to the Company's Board of Directors. His
appointment brings the number...